# 2025年10月31日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 创伤后癫痫与非创伤性癫痫退伍军人死亡率差异研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160793](https://pubmed.ncbi.nlm.nih.gov/41160793)
**期刊：** Neurology
**PMID：** 41160793
**DOI：** 10.1212/WNL.0000000000214344

### 第一部分 原文与翻译

**英文原标题：** Differences in Mortality Between Veterans With Posttraumatic and Nontraumatic Epilepsy.

**英文摘要原文：**
BACKGROUND AND OBJECTIVES: Higher mortality, relative to the general population, is associated with epilepsy and with particular types of traumatic brain injury (TBI). It is thus presumed that posttraumatic epilepsy (PTE), which indicates epilepsy after TBI, would have higher mortality relative to nontraumatic epilepsy (NTE). However, previous studies have not established a difference in mortality between PTE and NTE.

METHODS: We analyzed administrative data in the Veterans Health Administration to identify US military veterans diagnosed with epilepsy from 2005 to 2022 using previously validated criteria. PTE was defined as TBI documented in the 5 years before the epilepsy index date. TBIs were classified as skull/facial fracture, diffuse cerebral, focal cerebral, extracerebral, or concussion, based on International Classification of Diseases codes. Adjusted Kaplan-Meier survival curves and multivariable Cox proportional hazards models were fitted to compare mortality between PTE and NTE.

RESULTS: Among 210,182 veterans with epilepsy, 28,832 had PTE (mean onset age 52.6 years, 7.4% female) and 181,350 had NTE (mean onset age 60.9 years, 8.5% female). Mortality rate in PTE was higher compared with NTE and varied with the underlying TBI, being the highest with underlying diffuse cerebral injury (hazard ratio [HR] 1.17, 95% CI 1.07-1.28,  < 0.001), focal cerebral injury (HR 1.16, 95% CI 1.07-1.26,  < 0.001), or skull/facial fracture (HR 1.18, 95% CI 1.09-1.28,  < 0.001). However, underlying concussion had a mortality rate lower than all NTE combined (HR 0.91, 95% CI 0.86-0.95,  < 0.001). The relative mortality rate also varied with age at PTE onset, being the highest among young-onset PTE with extracerebral injury (HR 2.02, 95% CI 1.47-2.78,  < 0.001).

DISCUSSION: This study demonstrates that PTE leads to higher mortality compared with other forms of epilepsy, being up to 2 times higher in selected subgroups. The mechanism of underlying TBI influenced mortality rate. PTE after diffuse cerebral TBI, focal cerebral TBI, or skull/facial fractures led to higher mortality relative to NTE. Relative to NTE, young-onset PTE had the greatest rate of mortality. These results show that the age of PTE onset and the TBI precipitating PTE influence mortality and are relevant to consider in clinical practice. Future work should explore the reasons underlying higher mortality in PTE and refine TBI classification using additional data sources.

**中文摘要译文：**
背景与目的：与普通人群相比，癫痫和特定类型的创伤性脑损伤（TBI）均与较高的死亡率相关。因此推测，创伤后癫痫（PTE）——即TBI后发生的癫痫——相对于非创伤性癫痫（NTE）应具有更高的死亡率。然而，既往研究未能确定PTE与NTE之间的死亡率差异。

方法：我们分析了退伍军人健康管理局的行政数据，使用先前验证的标准识别2005年至2022年间诊断为癫痫的美国退伍军人。PTE定义为癫痫诊断日期前5年内有记录的TBI。根据国际疾病分类代码，将TBI分为颅骨/面部骨折、弥漫性脑损伤、局灶性脑损伤、脑外损伤或脑震荡。采用调整后的Kaplan-Meier生存曲线和多变量Cox比例风险模型比较PTE与NTE的死亡率。

结果：在210,182名癫痫退伍军人中，28,832人患有PTE（平均发病年龄52.6岁，7.4%为女性），181,350人患有NTE（平均发病年龄60.9岁，8.5%为女性）。PTE的死亡率高于NTE，且随基础TBI类型而异，其中基础弥漫性脑损伤（风险比[HR] 1.17，95% CI 1.07-1.28，P < 0.001）、局灶性脑损伤（HR 1.16，95% CI 1.07-1.26，P < 0.001）或颅骨/面部骨折（HR 1.18，95% CI 1.09-1.28，P < 0.001）的死亡率最高。然而，基础脑震荡的死亡率低于所有NTE合并组（HR 0.91，95% CI 0.86-0.95，P < 0.001）。相对死亡率也随PTE发病年龄而变化，在年轻发病的脑外损伤PTE患者中最高（HR 2.02，95% CI 1.47-2.78，P < 0.001）。

讨论：本研究表明，与其他形式的癫痫相比，PTE导致更高的死亡率，在特定亚组中可达2倍。基础TBI的机制影响死亡率。弥漫性脑TBI、局灶性脑TBI或颅骨/面部骨折后的PTE相对于NTE具有更高的死亡率。相对于NTE，年轻发病的PTE死亡率最高。这些结果表明，PTE发病年龄和诱发PTE的TBI影响死亡率，在临床实践中具有相关考虑价值。未来工作应探索PTE死亡率较高的原因，并使用额外数据源完善TBI分类。

### 第二部分 AI 大师评价

本研究通过分析21万余名退伍军人数据，首次明确证实创伤后癫痫（PTE）比非创伤性癫痫（NTE）具有更高的死亡率，填补了既往研究的空白。研究创新性地根据TBI具体类型进行分层分析，发现弥漫性脑损伤、局灶性脑损伤和颅骨骨折相关的PTE死亡率显著升高，而脑震荡相关PTE死亡率反而较低，这一发现对临床风险评估具有重要指导意义。研究还揭示了年轻发病PTE患者死亡率风险最高（HR达2.02），为高危人群识别提供了关键证据。虽然研究基于行政数据存在一定局限性，但其大样本量和详细分层分析为癫痫预后研究提供了重要范式，对改善PTE患者管理和预后评估具有重要临床价值。

---

## 2. 深度学习在癫痫患者治疗反应预测中的应用：我们能更快实现无癫痫发作吗？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160792](https://pubmed.ncbi.nlm.nih.gov/41160792)
**期刊：** Neurology
**PMID：** 41160792
**DOI：** 10.1212/WNL.0000000000214421

### 第一部分 原文与翻译

**英文原标题：** Deep Learning for the Prediction of Treatment Responses in Individuals With Epilepsy: Can We Get to Seizure Freedom Faster?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究探讨了深度学习技术在癫痫患者治疗反应预测中的应用前景。研究采用先进的深度学习算法，旨在通过分析患者临床数据来预测不同治疗方案的效果，从而帮助医生更快地为患者选择最有效的治疗策略。该研究的创新性在于将人工智能技术应用于癫痫治疗的精准化决策，有望显著缩短患者达到无癫痫发作状态的时间。然而，由于缺乏摘要信息，无法详细了解具体的研究方法、关键发现以及潜在的局限性，这在一定程度上影响了对其临床价值的全面评估。

---

## 3. 英夫利昔单抗治疗血管内治疗后难治性非缺血性脑增强异物肉芽肿性病变的有效性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160790](https://pubmed.ncbi.nlm.nih.gov/41160790)
**期刊：** Neurology
**PMID：** 41160790
**DOI：** 10.1212/WNL.0000000000214345

### 第一部分 原文与翻译

**英文原标题：** Effectiveness of Infliximab for Refractory Nonischemic Cerebral Enhancing Foreign-Body Granulomatous Lesions After Endovascular Therapy.

**英文摘要原文：**
OBJECTIVES: Nonischemic cerebral enhancing (NICE) foreign-body granulomatous lesions are an immune-mediated complication of endovascular therapy (EVT). No single immunotherapy has demonstrated consistent effectiveness. We highlight the novel use of tumor necrosis factor (TNF)-α inhibition in treating refractory NICE lesions.

METHODS: This multicenter case series describes 3 patients with refractory NICE lesions (recurrent seizures, persistent MRI enhancement, and/or steroid dependence with failure of ≥1 maintenance immunotherapy) treated with infliximab. Their clinical course, evaluation, and outcomes are detailed.

RESULTS: Patients were women (median age 57 years [range 56-58]), presenting with headache and seizures within 6 months of EVT for intracranial aneurysm (n = 2) or carotid stenosis (n = 1). MRI (n = 3) revealed unilateral nodular enhancement with vasogenic edema, and brain biopsy (n = 2) revealed foreign-body granulomatous inflammation. All patients developed refractory disease and steroid dependence despite ≥1 immunotherapy including mycophenolate (n = 3), rituximab (n = 1), and/or cyclophosphamide (n = 1). Infliximab treatment resulted in significant clinical and radiologic improvement in all 3 patients.

DISCUSSION: TNF-α inhibition may be an effective targeted treatment strategy for NICE foreign-body granulomatous lesions, expanding treatment options for patients with refractory disease. Larger prospective studies are needed to establish treatment guidelines aimed at improving outcomes in individuals with refractory disease.

CLASSIFICATION OF EVIDENCE: This article provides Class IV evidence that infliximab may offer potential benefit in patients with NICE lesions after EVT.

**中文摘要译文：**
目的：非缺血性脑增强（NICE）异物肉芽肿性病变是血管内治疗（EVT）的一种免疫介导并发症。目前尚无单一免疫疗法显示出持续有效性。我们重点介绍了肿瘤坏死因子（TNF）-α抑制在治疗难治性NICE病变中的创新应用。

方法：本多中心病例系列描述了3例接受英夫利昔单抗治疗的难治性NICE病变患者（复发性癫痫发作、持续性MRI增强和/或类固醇依赖且≥1种维持免疫治疗失败）。详细介绍了他们的临床病程、评估和结局。

结果：患者均为女性（中位年龄57岁[范围56-58岁]），在因颅内动脉瘤（n=2）或颈动脉狭窄（n=1）接受EVT后6个月内出现头痛和癫痫发作。MRI（n=3）显示单侧结节状增强伴血管源性水肿，脑活检（n=2）显示异物肉芽肿性炎症。尽管接受了包括霉酚酸酯（n=3）、利妥昔单抗（n=1）和/或环磷酰胺（n=1）在内的≥1种免疫治疗，所有患者仍发展为难治性疾病和类固醇依赖。英夫利昔单抗治疗使所有3例患者均获得了显著的临床和影像学改善。

讨论：TNF-α抑制可能是NICE异物肉芽肿性病变的一种有效靶向治疗策略，为难治性疾病患者扩展了治疗选择。需要更大规模的前瞻性研究来建立旨在改善难治性疾病患者预后的治疗指南。

证据分类：本文提供了IV类证据，表明英夫利昔单抗可能为EVT后NICE病变患者带来潜在获益。

### 第二部分 AI 大师评价

本研究核心目的是探索英夫利昔单抗在治疗血管内治疗后难治性非缺血性脑增强异物肉芽肿性病变中的有效性。研究采用多中心病例系列方法，对3例经传统免疫治疗无效的难治性患者进行了详细分析。关键发现显示，TNF-α抑制剂英夫利昔单抗在所有患者中均产生了显著的临床和影像学改善。该研究的创新性在于首次系统评估了TNF-α抑制在这一罕见并发症中的应用价值，为临床治疗提供了新的靶向策略。虽然样本量较小且证据等级为IV类，但这一发现为治疗这一具有挑战性的神经系统并发症开辟了新的方向，具有重要的临床转化价值。

---

## 4. 基于基因组和临床数据整合深度学习预测新诊断癫痫治疗反应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160788](https://pubmed.ncbi.nlm.nih.gov/41160788)
**期刊：** Neurology
**PMID：** 41160788
**DOI：** 10.1212/WNL.0000000000214315

### 第一部分 原文与翻译

**英文原标题：** Integrative Deep Learning of Genomic and Clinical Data for Predicting Treatment Response in Newly Diagnosed Epilepsy.

**英文摘要原文：**
BACKGROUND AND OBJECTIVES: Epilepsy is a common neurologic disorder. Although antiseizure medications (ASMs) are the first-line treatment, identifying the most effective ASM for each individual remains a trial-and-error process. Genetic variation may influence treatment response. We aimed to develop and validate a multimodal deep learning model that integrates clinical and genomic features to predict response to the initial ASM in people with newly diagnosed epilepsy.

METHODS: We used data from individuals with newly diagnosed epilepsy in Australia as the development cohort and participants from the Human Epilepsy Project 1 (recruited in the United States, Europe, and Australia) as the external validation cohort. All participants initiated ASM treatment and were followed prospectively for at least 1 year. We included 16 clinical factors and constructed 4 genomic feature types related to epilepsy and ASM pharmacogenomics, with and without functional impact annotations. We evaluated various machine learning architectures and multimodal fusion strategies to predict seizure freedom while taking the initial ASM at 1 year.

RESULTS: In the development cohort (n = 286, median age 39 years, 47.2% seizure free), combining clinical and genomic features in our proposed multimodal deep learning model improved predictive performance. The highest area under the receiver operating characteristic curve (AUC) of 0.74 (95% CI 0.70-0.78) was achieved using clinical factors and genomic variants affecting transcription factor binding, significantly outperforming the clinical-only model (AUC 0.67, 95% CI 0.62-0.72;  < 0.05). In the external validation cohort (n = 219, median age 31 years, 20.5% seizure free), the same feature combination achieved an AUC of 0.69 (95% CI 0.67-0.71), higher than the clinical-only model (AUC 0.62, 95% CI 0.60-0.64;  < 0.05). Applying this model to the development cohort, if all participants took the highest ranked ASMs, the mean predicted seizure-free probability would be 68.05% (95% CI 65.79%-70.35%) compared with the observed seizure-free rate of 47.2% (95% CI 41.3%-53.2%).

DISCUSSION: Integrating genomic data with clinical features enhances the ability of deep learning models in predicting ASM response in newly diagnosed epilepsy. This approach may support personalized treatment selection and improve clinical outcomes.

**中文摘要译文：**
背景与目的：癫痫是一种常见的神经系统疾病。尽管抗癫痫药物（ASMs）是一线治疗方法，但为每个个体确定最有效的ASM仍然是一个试错过程。遗传变异可能影响治疗反应。我们旨在开发和验证一种多模态深度学习模型，该模型整合临床和基因组特征，以预测新诊断癫痫患者对初始ASM的反应。

方法：我们使用澳大利亚新诊断癫痫患者的数据作为开发队列，并使用人类癫痫项目1（在美国、欧洲和澳大利亚招募）的参与者作为外部验证队列。所有参与者均开始ASM治疗，并前瞻性随访至少1年。我们纳入了16个临床因素，并构建了4种与癫痫和ASM药物基因组学相关的基因组特征类型，包括和不包括功能影响注释。我们评估了各种机器学习架构和多模态融合策略，以预测服用初始ASM1年时的无癫痫发作状态。

结果：在开发队列中（n = 286，中位年龄39岁，47.2%无癫痫发作），在我们提出的多模态深度学习模型中结合临床和基因组特征提高了预测性能。使用临床因素和影响转录因子结合的基因组变异获得了最高的受试者工作特征曲线下面积（AUC）0.74（95% CI 0.70-0.78），显著优于仅临床模型（AUC 0.67，95% CI 0.62-0.72；< 0.05）。在外部验证队列中（n = 219，中位年龄31岁，20.5%无癫痫发作），相同的特征组合实现了AUC 0.69（95% CI 0.67-0.71），高于仅临床模型（AUC 0.62，95% CI 0.60-0.64；< 0.05）。将该模型应用于开发队列，如果所有参与者都服用排名最高的ASMs，预测的无癫痫发作概率平均为68.05%（95% CI 65.79%-70.35%），而观察到的无癫痫发作率为47.2%（95% CI 41.3%-53.2%）。

讨论：将基因组数据与临床特征相结合，增强了深度学习模型预测新诊断癫痫ASM反应的能力。这种方法可能支持个性化治疗选择并改善临床结局。

### 第二部分 AI 大师评价

本研究开发了一种创新的多模态深度学习模型，整合临床和基因组数据来预测新诊断癫痫患者的抗癫痫药物反应。研究采用澳大利亚开发队列和国际多中心验证队列，纳入了16个临床因素和4种基因组特征类型，通过先进的机器学习架构实现了对治疗反应的精准预测。关键发现显示，结合临床因素和影响转录因子结合的基因组变异可将预测性能提升至AUC 0.74，显著优于仅临床模型，并在外部验证中保持稳健性能。这项研究的创新性在于首次系统地将深度学习技术应用于癫痫药物基因组学领域，为个性化抗癫痫治疗提供了重要工具，有望改变目前试错式的治疗模式，具有重要的临床转化价值。虽然模型性能仍有提升空间，但为精准医学在神经疾病领域的应用开辟了新途径。

---

速递结束，祝您工作愉快！